Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride

被引：0
|
作者：
Bode, B. W. [1 ]
Hale, P. M. [2 ]
Hammer, M. [3 ]
Testa, M. A. [4 ]
Garber, A. [5 ]
机构：
[1] Atlanta Diabet Associates, Atlanta, GA USA
[2] Novo Nordisk Inc, Princeton, NJ USA
[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Baylor Coll Med, Houston, TX 77030 USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
894
引用
收藏
页码：S357 / S358
页数：2
相关论文
共 50 条
  • [31] The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, liraglutide
    Steensgaard, Dorte B.
    Thomsen, Jens K.
    Olsen, Helle B.
    Knudsen, Lotte B.
    DIABETES, 2008, 57 : A164 - A164
  • [32] The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects
    Jiang, Ji
    Zhang, Jianyan
    Jacobsen, Lisbeth V.
    Hu, Pei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1620 - 1627
  • [33] The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels
    Flint, A.
    Kapitza, C.
    Hindsberger, C.
    Zdravkovic, M.
    DIABETOLOGIA, 2008, 51 : S354 - S354
  • [34] The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline corrected postprandial glucose levels
    Flint, Anne
    Kapitza, Christoph
    Hindsberger, Charlotte
    Zdravkovic, Milan
    DIABETES, 2008, 57 : A165 - A165
  • [35] Liraglutide, a Once-Daily Human GLP-1 Analog, Reduces Systolic Blood Pressure with Minimal Impact from Weight Loss in Subjects with Type 2 Diabetes.
    Henry, R. R.
    Fonseca, V.
    Tabanera y Palacios, R.
    Brett, J.
    Plutzky, J.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [36] Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
    Matthews, D. R.
    Marre, M.
    Le-Thi, T. D.
    Zdravkovic, M.
    Simo, R.
    Garber, A.
    Zinman, B.
    DIABETOLOGIA, 2008, 51 : S356 - S356
  • [37] Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
    Chatterjee, Dhruba J.
    Khutoryansky, Naum
    Zdravkovic, Milan
    Sprenger, Craig R.
    Litwin, Jeffrey S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (11): : 1353 - 1362
  • [38] The once-daily human GLP-1 analog liraglutide substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline
    Nauck, Michael
    Brandle, Michael
    Vaag, Allan
    Colagiuri, Stephen
    Schmitz, Ole
    Zdravkovic, Milan
    Hermansen, Kyeld
    DIABETES, 2008, 57 : A594 - A594
  • [39] Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
    Garber, A.
    Henry, R. R.
    Ratner, R.
    Hale, P.
    Chang, C. T.
    Bode, B.
    DIABETES OBESITY & METABOLISM, 2011, 13 (04): : 348 - 356
  • [40] Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
    Joffe, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (16) : 1326 - 1336
12345